RGC 1503 / ABVC BioPharma, Rgene Corp - LARVOL DELTA

ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation (GlobeNewswire) - "ABVC Biopharma, Inc...announced that it has expanded its co-development partnership with Rgene Corporation. BioKey...has entered into a Clinical Development Service Agreement with Rgene to guide three Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for the treatment of pancreatic cancer and RGC 1503 for the treatment of colorectal cancer patients...Under the terms of the new Services Agreement, BioKey is eligible to receive payments totaling $3.0 million over a 3-year period with each payment amount to be determined by certain regulatory milestones obtained during the agreement period....BLEX 404, the new drug under clinical development covered by the service agreement...with breast cancer and myelodysplastic syndromes (MDS) patients."

Licensing / partnership • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lung Cancer • Myelodysplastic Syndrome • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor